Polycythemia Vera
Recommended Therapies for Polycythemia Vera Underused
December 04, 2018Phlebotomy and hydroxyurea tied to improved survival, lower risk for thrombosis in older patients.
Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
August 15, 2018In a retrospective analysis, researchers sought to determine the use of cytoreductive therapies in patients with high-risk and low-risk PV.
A Case Study on Polycythemia Vera: Diagnosis Through CBC Management With Ruxolitinib
July 27, 2018This case follows a 35-year-old man with polycythemia vera from presentation in the ED through initiating and modifying treatment with phlebotomy and hydroxyurea, and eventually achieving optimal management of symptoms and CBC with ruxolitinib.
Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
January 17, 2018Researchers assessed outcomes for 587 patients with PV to determine the risk factors most likely to predict arterial or venous thrombosis in this patient population.
Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera
December 11, 2017Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.
Ruxolitinib Not Superior to Second-line Treatments for Essential Thrombocythemia
November 03, 2017A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
A Case of Newly Diagnosed PCV After Relapse TTP Complicated by Undiagnosed RA
October 03, 2017This case of a 63-year-old African American male with a complicated history illustrates the need for a comprehensive risk assessment of thrombosis in patients with primary polycythemia vera, especially those with concomitant conditions that predispose to thrombosis.
A Patient's Guide to Managing Symptoms of Polycythemia Vera (Fact Sheet)
September 15, 2017This fact sheet reviews common symptoms associated with polycythemia vera (PV) and how a patient may address them, along with an overview of more serious symptoms that require medical attention.
Arthritis Medication Shows Potential in the Treatment of Polycythemia Vera
August 21, 2017Methotrexate, a medication used commonly in the treatment of arthritis, shows promise as a treatment for polycythemia vera, a blood cancer classified as a myeloproliferative neoplasm.
First Case of Dermatomyositis Associated with Secondary Myelofibrosis Following Polycythemia Vera
June 30, 2017A male patient with a history of polycythemia vera that converted to myelofibrosis becomes a first known case of dermatomyositis associated with secondary myelofibrosis.
Unexplained Leukocytosis, Thrombocytosis in MPN Warrants Evaluation for CML
June 05, 2017A chart review reveals 3 cases of CML developing in patients with diagnoses of ET and PV.
New Predisposition Genes for Familial Polycythemia Vera Are Identified
May 02, 2017Predisposition genes for familial polycythemia vera were identified via exome sequencing in a Finnish family with 4 patients.
Continued Hydroxyurea vs Switching to Ruxolitinib for Polycythemia Vera
November 21, 2016Ruxolitinib is proven superior to best available therapy for polycythemia vera with inadequate response or intolerance of hydroxyurea. This study evaluates the impact of continued hydroxyurea vs switching to ruxolitinib on disease-related symptom burden.
Women With Myeloproliferative Neoplasms Appear to Have Successful Pregnancies
November 02, 2016Evidence suggests that women with myeloproliferative neoplasms have a higher risk of maternal and fetal complications. In this data analysis, researchers evaluated outcomes for pregnant women with essential thrombocythemia, polycythemia, or myelofibrosis and their infants.
Polycythemia Vera (Fact Sheet)
October 27, 2016This fact examines the possible causes, risk factors, symptoms, and treatments associated with polycythemia vera.
Hydroxyurea May Improve Kidney Function in PV-Associated Nephrotic Syndrome
October 21, 2016The clinical course of a patient with polycythemia vera and proteinuria whose biopsy lead to a diagnosis of focal segmental glomerulosclerosis is described.
Patients With MPNs, Physicians View Treatment Goals Differently
October 07, 2016Patients with myeloproliferative neoplasms, such as polycythemia vera and myelofibrosis, and their physicians frequently view the assessment of disease prognosis, disease burden, and treatment goals differently.
Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
September 27, 2016Ruxolitinib is an effective long-term treatment option for patients with polycythemia resistant or intolerant to hydroxyurea, according to a study presented at the 2016 European Hematology Association Congress.
Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
September 22, 2016[Blood and Lymphatic Cancer: Targets and Therapy] This research provides a summary of the pathobiology of polycythemia vera, and examines challenges associated with traditional PV treatment options and the clinical data for ruxolitinib.
Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
September 20, 2016High platelet counts and hemoglobin/hematocrit levels may be associated with hearing loss in patients with polycythemia vera.
High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
September 19, 2016Patients with polycythemia vera enrolled in the REVEAL trial have high symptom burden resulting in substantial physical and emotional quality of life impairment and notable work productivity loss.
Study Assesses Risk of Secondary AML in Patients With Myeloproliferative Neoplasms
September 16, 2016Among patients with myeloproliferative neoplasms, men with primary myelofibrosis diagnosed after 2006 are at the highest risk of developing secondary acute myeloid leukemia (AML).
FDA Approves Ruxolitinib for Polycythemia Vera
December 12, 2014Drug is approved for patients who cannot tolerate or have an inadequate response to other meds.
Sign Up for Free e-newsletters
ONA Articles
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Shorter Duration of Cryotherapy as Effective as Standard Therapy Prior to HSCT for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- 9/11 Responders May Have Higher Head and Neck Cancer Risk
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |